21
Sep 23
06
Sep 23
31
Aug 23
10
Aug 23
09
Aug 23
12
Jun 23
06
Jun 23
23
May 23
15
May 23
20
Mar 23
CalciMedica Acute Pancreatitis Clinical Experts Event
Listen to the Webcast
CalciMedica Announces Upcoming Presentations and Events in September
LA JOLLA, Calif. , Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023
LA JOLLA, Calif. , Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS), in India Expansion of team with key leadership appointments in regulatory and clinical development Filing of an investigational
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif. , Aug. 09, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (NASDAQ: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium
CalciMedica Announces Relisting on Nasdaq
LA JOLLA, Calif. , June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced that The Nasdaq Stock Market LLC has
CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP Data show that inhibiting Orai1-mediated store-operated Ca 2+ entry (SOCE) with a selective CRAC channel inhibitor prevented the progression of RAP and
CalciMedica Expands Executive Team with New Appointments
Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development LA JOLLA, Calif. , May 23, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
LA JOLLA, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter
CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results in acute pancreatitis for
Displaying 1 - 10 of 11